Companies in China are jostling for access to Nvidia’s latest Rubin lineup while better-funded U.S. competitors are first in ...
First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment — — Savolitinib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results